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Abstract 
Background: Anoctamin 1 (ANO1 or TMEM16A) Ca2+-gated Cl− channels of nociceptor neurons are emerging as 
important molecular components of peripheral pain transduction. At physiological intracellular Cl− concentrations 
([Cl−]i) sensory neuronal Cl
− channels are excitatory. The ability of sensory neuronal ANO1 to trigger action potentials 
and subsequent nocifensive (pain) responses were examined by direct activation with an N-aroylaminothiazole. ANO1 
channels are also activated by intracellular Ca2+ ([Ca2+]i) from sensory neuronal TRPV1 (transient-receptor-potential 
vallinoid 1) ion channels and other noxicant receptors. Thus, sensory neuronal ANO1 can facilitate TRPV1 triggering 
of action potentials, resulting in enhanced nociception. This was investigated by reducing ANO1 facilitation of TRPV1 
effects with: (1) T16A[inh]-A01 ANO1-inhibitor reagent at physiological [Cl−]i and (2) by lowering sensory neuronal 
[Cl−]i to switch ANO1 to be inhibitory.
Results: ANO1 effects on action potential firing of mouse dorsal root ganglia (DRG) neurons in vitro and mouse 
nocifensive behaviors in vivo were examined with an N-aroylaminothiazole ANO1-activator (E-act), a TRPV1-activator 
(capsaicin) and an ANO1-inhibitor (T16A[inh]-A01). At physiological [Cl−]i (40 mM), E-act (10 µM) increased current 
sizes (in voltage-clamp) and action potential firing (in current-clamp) recorded in DRG neurons using whole-cell elec-
trophysiology. To not disrupt TRPV1 carried-Ca2+ activation of ANO1 in DRG neurons, ANO1 modulation of capsaicin-
induced action potentials was measured by perforated-patch (Amphotericin–B) current-clamp technique. Subse-
quently, at physiological [Cl−]i, capsaicin (15 µM)-induced action potential firing was diminished by co-application 
with T16A[inh]-A01 (20 µM). Under conditions of low [Cl−]i (10 mM), ANO1 actions were reversed. Specifically, E-act 
did not trigger action potentials; however, capsaicin-induced action potential firing was inhibited by co-application of 
E-act, but was unaffected by co-application of T16A[inh]-A01. Nocifensive responses of mice hind paws were dra-
matically induced by subcutaneous injections of E-act (5 mM) or capsaicin (50 µM). The nocifensive responses were 
attenuated by co-injection with T16A[inh]-A01 (1.3 mM).
Conclusions: An ANO1-activator (E-act) induced [Cl−]i-dependent sensory neuronal action potentials and mouse 
nocifensive behaviors; thus, direct ANO1 activation can induce pain perception. ANO1-inhibition attenuated capsa-
icin-triggering of action potentials and capsaicin-induced nocifensive behaviors. These results indicate ANO1 chan-
nels are involved with TRPV1 actions in sensory neurons and inhibition of ANO1 could be a novel means of inducing 
analgesia.
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Background
Acute peripheral pain is an essential sensation evolved 
to deter exposure of normal tissues to harmful environ-
ments and to prevent further injury of damaged and 
inflamed tissues. Peripheral neuropathies and inflamma-
tory conditions can heighten pain perception to noxious 
stimuli (hyperalgesia) and change the perception of non-
noxious stimuli to be painful (allodynia). For millions of 
people, the hyperalgesia and allodynia occurs chronically 
and becomes intolerable and debilitating. Some common 
examples are back injuries, diabetic neuropathy, arthri-
tis, dermatitis, oral and ocular diseases [1, 2]. Chronic 
peripheral pain not only alters the quality of life, but also 
costs billions of dollars due to the loss of work productiv-
ity and the health care to alleviate and manage the pain, 
including chronic medications [2, 3]. Great strides have 
been made to improve pain management. However, the 
physiological and pathophysiological molecular compo-
nents of peripheral pain, hyperalgesia, allodynia and the 
progression from acute to chronic pain, as well as the 
effects of targeting these sites with pharmaceuticals, are 
not yet fully understood.
Acute peripheral pain transduction is mediated by 
unmyelinated C-fiber and thinly myelinated Aδ fiber 
nociceptive neurons. The peripheral terminals of these 
somatosensory neurons express specific receptors for: 
(1) environmental hazards (extreme temperatures, reac-
tive chemicals…) and (2) signaling factors released by 
damaged and inflamed tissues. Activation of the recep-
tors evokes a graded depolarizing potential and often an 
increase of intracellular Ca2+, [Ca2+]i. If depolarization 
reaches levels to activate voltage-gated Na+ channels, 
then action potentials (APs) propagate along the pro-
cesses to central terminal glutaminergic/peptidergic syn-
apses. Subsequent activation of spinal/brainstem neurons 
elicits reflexes and transmits signals via lateral spinotha-
lamic and related tracts to brain neurons. The brain filters 
and interprets the signals and executes the perception of 
pain and other protective responses [4]. Nociceptive neu-
rons with injuries or innervating continuously inflamed 
tissues can become hypersensitivity to endogenous fac-
tors and environmental hazards. The pathophysiologi-
cal change in sensory neurons contribute significantly to 
evoking hyperalgesia and allodynia [5]. Central nervous 
system neurons are also involved in the perception of 
hyperalgesia and allodynia.
Recently, sensory neuronal Anoctamin 1 (ANO1) Ca2+-
gated Cl− channels have emerged as an important molec-
ular component of nociception transduction in response 
to hazardous environmental stimuli and inflammatory 
signals. ANO1 channels also contribute to the related 
phenomena of hyperalgesia and allodynia [6–9]. Insights 
into sensory neuronal ANO1 contribution to nociception 
have emerged from its thermo-sensor properties and 
activation by increased [Ca2+]i induced by inflamma-
tory signaling factors and noxious environmental stimuli, 
as well as, the physiological functions of ANO1 in other 
tissues. However, the precise mechanisms of nociceptive 
function of ANO1 channels in sensory neurons requires 
further study.
ANO1 (also known as TMEM16A, DOG-1, ORAOV2 
or TAOS-2) are channel proteins putatively formed 
of eight transmembrane spans arranged in a dimer 
[10–13]. In addition to somatosensory neurons, ANO1 
channels are expressed in a variety of excitatory, secre-
tory and other cell types [14–16]. ANO1 channels 
carry outward rectifying anion currents gated by heat 
and [Ca2+]i (with KD50 in the submicromolar range), 
and pharmacological agents [17, 18]. Due to their high 
cytosolic Cl− concentrations, [Cl−]i and consequential 
Cl− electrochemical equilibrium (ECl−), sensory neuron 
Cl− channels are excitatory; in contrast, central neuronal 
Cl− channels are inhibitory [18]. Therefore, sensory neu-
ronal ANO1 channels are presumed to participate as 
depolarizing Cl− effluxes at resting potentials that can 
contribute to triggering APs [9].
ANO1 mediates the AP propagation and subsequent 
pain-like nociception to proteases released and activated 
by damaged and inflamed tissues; M-type K+ channels 
and transient-receptor-potential (TRP) cation channels 
are also involved. The proteases and their products, such 
as bradykinin (BK), are detected by sensory neuronal 
G-protein coupled receptors (GPCRs). Specifically, BK 
GPCR activation results in inositol-triphosphate (IP3) 
gating of IP3-receptor channels to release Ca2+ from 
intracellular stores. In sensory neurons, IP3-receptors 
are coupled with ANO1, thereby they directly deliver-
ing a large localized concentration of Ca2+ to activate 
ANO1 channels [6, 7]. The ensuing ANO1 depolarizing 
Cl− fluxes then trigger APs that result in pain percep-
tion to the site of injury/inflammation. PAR2 (proteinase 
activated receptor-2) appears to activate nociceptive neu-
ronal ANO1 by a similar mechanism [7].
ANO1, TRP channels, and other channels expressed on 
nociceptive neurons, detect elevated environmental tem-
peratures and respond by membrane depolarization [20–
23]. These specialized channels combine with the other 
thermosensitive channels to code the magnitude of heat 
intensity that results in the spectrum of psychophysical 
perception of temperature from comfortably warm to 
painfully hot [8, 24]. The best characterized of the ther-
mosensitive channels are TRPV1 (TRP vallinoid 1) chan-
nels. Mammalian TRPV1 channels are responsible for 
the ‘hot’ sensation of capsaicin, the pungent ingredient of 
chili peppers; TRPV1 are also involved in general nocic-
eption, hyperalgesia and pro-inflammatory neuropeptide 
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release [24–27]. TRPV1 channels carry cations including 
Ca2+ that depolarize neurons [28]. TRPV1 and ANO1 
are highly expressed and co-localized in nociceptive neu-
rons [24, 30]. Recently, it has been shown that sensory 
neuronal TPRV1 and ANO1 channels interact. Thus, 
TRPV1-carried [Ca2+]i can gate ANO1 in a manner simi-
lar to [Ca2+]i induced by BK [31–34]. At physiological 
[Cl−]i, TRPV1-carried Ca2+ gating of ANO1 channels 
result in depolarizing Cl− effluxes and combining with 
TRPV1 carried cation influxes to facilitate the triggering 
of APs. Thereby, pain perception and associated nocifen-
sive behaviors to TRPV1 stimulation are intensified. This 
could be especially pronounced in heat detection, where 
ANO1 would be directly activated by heat and in direct 
activation by [Ca2+]i from TRPV1, which is also activated 
by heat [23]. Contrariwise, sensory neuronal APs and 
painful responses by TRPV1 stimulation could be either 
diminished by blocking ANO1 channels or by lowering 
sensory neuronal [Cl−]i enough to switch ANO1-carried 
Cl− fluxes to be inhibitory.
Our research examined ANO1 involvement in noci-
ception by: (1) manipulating [Cl−]i and (2) using phar-
macological tools to activate or inhibit ANO1 channels 
activity. We used an N-aroylaminothiazole ANO1-
activator reagent, E-act, to induce ANO1-like electro-
physiological currents in sensory neurons and evoke 
[Cl−]i–dependent action potentials that were inde-
pendent of heat or [Ca2+]i. Furthermore, subcutaneous 
applications of E-act into mouse paws, in  vivo, induced 
nocifensive behaviors. To the best of our knowledge, 
these studies are the first to demonstrate that direct acti-
vation of ANO1 channels by a pharmacological reagent 
results in sensory neuron APs and pain-associated noci-
ceptive behaviors. This shows ANO1 activation alone is 
sufficient to trigger APs and implies direct activation of 
ANO1 can produce pain. Thus, ANO1 activation could 
be involved in facilitating the effects of many noxicants 
and a variety of pain disorders.
Pharmacological inhibitors of ANO1 have been exam-
ined in sensory neurons to diminish BK effects [6]. Our 
research similarly used inhibitors of ANO1 to diminish: 
1) the in vitro effects of TRPV1 activation by capsaicin on 
sensory neuronal AP firing, and 2) in vivo mouse nocif-
ensive behavioral responses [25–28]. We report here 
that co-application with ANO1-inhibitor, T16A[inh]-
A01 (ANO1-inh), attenuated capsaicin-induced sensory 
neuronal AP firing at physiological [Cl−]i. At low [Cl−]i, 
ANO1 channels are inhibitory. Therefore, ANO1-inh 
inhibitory effects were absent and instead direct activa-
tion of ANO1 by E-act diminished capsaicin-induced 
APs. Subcutaneous co-applications of ANO1-inh dimin-
ished mouse nocifensive behavioral responses to capsai-
cin [34]. These results indicate: (1) ANO1 Cl− channels 
modulate TRPV1 channels effects and (2) the potential 
of specific pharmaceutical inhibitors of ANO1 as local 
anesthetics.
Results
E‑act activates and T16A[inh]‑A01 inhibits ANO1 
in transfected HEK‑293 cells
Our studies examined ANO1 Cl− channels’ function 
in dorsal root ganglia (DRG) neurons and their role in 
mouse nociception/pain. Pivotal to these studies were 
pharmacological manipulation of ANO1 channels 
expressed in DRG neurons by an N-aroylaminothiazole 
ANO1-activator, E-act, and ANO1-inhibitor, T16A[inh]-
A01 (ANO1-inh). Namkung et  al., 2011, originally dis-
covered and characterized E-act’s ability to activate 
ANO1 by: (1) Cl− (I−) imaging and electrophysiology 
of salivary and airway cells and recombinant ANO1-
expressing cells and (2) measuring bronchi submucosal 
glands stimulation and intestinal smooth muscle contrac-
tions [18]. ANO1-inh was also discovered by the same 
laboratory group using similar methods [35]. Following 
their discovery, ANO1-inh has been a powerful tool for 
inhibiting ANO1 channels in studies of the epithelia and 
the vasculature as well as bradykinin actions in sensory 
neurons [7, 36–38]. E-act (10  µM) activation of ANO1 
and ANO1-inh (20  µM) inhibition of E-act effects were 
verified with whole-cell patch-clamp electrophysiology 
of recombinant mouse ANO1 (mANO1) transfected 
in HEK-293t cells. Currents were recorded to voltage 
ramps of −100 to +100  mV over 200  ms at every sec-
ond; in between ramps, potential was held (VH) to 0 mV. 
E-act application induced large sigmoidal or linear cur-
rent–voltage curves (Fig. 1a). Therefore, inward currents 
at −80  mV and outward currents at +80  mV were on 
average equal sizes (Fig. 1b). The linear current–voltage 
curves were similar for mANO1 current–voltage curves 
activated by high [Ca2+]i (10 µM or more) and were also 
inhibited by 20 µM ANO1-inh [39]. Individual mANO1 
inward current sizes (at −80  mV) and outward current 
sizes (at +80  mV) that were recorded at 10  µM-[Ca2+]i 
are displayed (n  =  4) in Additional file  1: Figure S1. 
mANO1 currents inactivated spontaneously in several 
recordings and were excluded in our studies. It is possible 
ANO1-inh effects on ANO1 currents at 10  µM-[Ca2+]i 
are skewed by channel inactivation.
E‑act activates and T16A[inh]‑A01 inhibits ANO1 in DRG 
neurons
ANO1 expression in DRG neurons has been well estab-
lished [24, 40]. Inward currents at −60  mV in DRG 
neurons have been deduced to be ANO1 currents. The 
currents are increased by [Ca2+]i from activation of BK-
GPCR or TRPV1 and then inhibited by ANO1-inh or 
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other Cl− channel inhibitors [7, 32]. To further under-
stand ANO1 channels physiology in DRG neurons, we 
recorded whole-cell currents to voltage ramps from 
−100 to +100 mV in mouse primary cultured DRG neu-
rons in response to direct activation of ANO1 by E-act. 
E-act (10 µM) perfusion induced outward rectifying cur-
rent–voltage curves that were subsequently inhibited by 
co-application with 20 µM ANO1-inh; 12 out of 18 DRG 
neurons tested showed E-act induced currents, how-
ever, only 7 of these patches were used with ANO1-inh 
(Fig.  1c). As shown in Fig.  1d, the average inward cur-
rents (at −80 mV) induced by E-act were minimal, while 
relatively large average outward currents (at +80  mV) 
occurred. Currents were recorded every second for 
200 ms with VH = −70 mV. Recording-pipette solutions 
contained Cs+ to block K+ channels and extracellular 
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Fig. 1 ANO1 currents are induced by ANO1-activator and diminished by ANO1-inhibitor in mouse DRG neurons and transfected HEK-293 cells. a 
Traces of currents recorded to voltages ramped from −100 to +100 mV of a representative mANO1 transfected HEK-293t cell (mANO1-HEK293): 
before perfusion (blue trace Pre) and following bath perfusions of N-aroylaminothiazole (E-act, 10 µM, red trace) activating ANO1, and sequential 
inhibition of E-act effects by mixing in ANO1-inhibitor T16A[inh]-A01 (ANO1-inh, 20 µM, green trace). Recording pipettes had 0-Ca2+; VH = 0 mV. b 
Averaged current sizes recorded at −80 mV and +80 mV (black lines), increased following 10 µM E-act (black bar at 70 s) and decreased by ANO1-
inh with E-act (white bar at 140 s) bath perfusions for mANO1-HEK293 cells (n = 3). Gray lines represent SE. c Traces of ANO1-like outwardly rectifying 
currents recorded to voltages ramped from −100 to +100 mV of a representative DRG neuron: before activation (blue trace Pre), activation by 10 µM 
E-act (red trace) bath perfusion, and inhibition by a perfusion mixture of E-act with 20 µM ANO1-inh (green trace). d Average current sizes recorded 
at −80 mV and +80 mV (black lines), following 10 µM E-act (black bar at 80 s) perfusion and a sequential perfusion mixture of 20 µM ANO1-inh 
with E-act (white bar at 180 s) for DRG neurons (n = 7). Gray lines represent SE. In DRG neurons (c, d), all bath and applications contained 10 µM 
ruthenium red to block TRP channels and recording pipette contained 0-Ca2+. VH = −70 mV. All intracellular solutions were CsCl-based. Records of 
currents were made over 200 ms at 1 Hz intervals in the whole-cell configuration
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solutions contained ruthenium red (10 µM) to block TRP 
and other divalent cation channels.
The lack of large inward currents was surprising con-
sidering that: (1) receptor-mediated [Ca2+]i activation of 
ANO1 in DRG neurons induced large (>400 pA) inward 
currents at −60  mV and (2) our recordings of E-act 
inducing large inward currents (linear current–voltage 
curves) for recombinant ANO1 [7, 32]. However, record-
ings of native ANO1 reported in other tissues are very 
similar to E-act-induced outward rectifying currents 
in DRG neurons [6, 33]. Moreover, recombinant ANO1 
current–voltage curves induced by 1  µM or less [Ca2+]i 
have similar outward rectification as native ANO1 [38]. 
E-act induced DRG currents being attributed to ANO1 
channels activation and not to off target effects were sup-
ported by: (1) E-act induction of currents in recombinant 
ANO1 expressing cells and (2) co-application of ANO1-
inh reduction of the E-act induced currents in DRG 
neurons. ANO1-inh does not have actions on sensory 
neuronal voltage-gated Na+, Ca2+ or K+ channels [32]. 
In certain experiments, VH was switched from −70 to 
0 mV (and vice versa) to assure that: (1) outward rectifi-
cation was not due to voltage regulation of ANO1 and (2) 
E-act or ANO1-inh did not interfere with voltage-gated 
Na+ channels (VH =  0  mV closes certain, albeit not all, 
voltage-gated Na+ channels by the inactivation h-gate). 
Under these conditions, there was no noticeable effect 
(data not shown).
E‑act evokes action potentials in DRG neurons dependent 
on [Cl−]i
Sensory neurons have relatively high (~40 mM) intracel-
lular Cl−, [Cl−]i, thus the Cl− electrochemical equilib-
rium (ECl-) is approximately −30 mV [19]. This is near the 
voltage required to activate voltage-gated Na+ channels 
responsible for action potential (AP) propagation. We 
examined if at high [Cl−]i, (160 mM; ECl− = 1.1 mV) or 
physiological/mid [Cl−]i (40  mM; E−Cl = −34  mV), acti-
vation of ANO1 channels would trigger APs in sensory 
neurons. While, at low [Cl−]i (10 mM, ECl− = −69 mV), 
ANO1 activation would inhibit AP firing. Whole-cell cur-
rent clamp electrophysiology of primary cultured DRG 
neuronal membrane potential (Vm) was used to record 
APs (Vm spikes above 10  mV were considered APs). 
Currents were injected to adjust the non-excited Vm to 
−30 ± 10 mV, a level slightly below, the voltage necessary 
to activate voltage-gated channels. Voltage-gated chan-
nels responsible for APs were then reset by current injec-
tions to bring Vm to −70 ± 10 mV [40] (Fig. 2a).
Direct activation of sensory neuronal ANO1 by E-act 
(10  µM) bath perfusion significantly increased APs 
from baseline when [Cl−]i was at high [Cl−]i (n =  3) or 
mid [Cl−]i (n = 3). The average APs for 25 s occurring at 
baseline and after E-act are presented in Fig.  2b. {Aver-
age APs for: High [Cl−]i at baseline  =  10.3  ±  1.4 and 
E-act = 21.7 ± 2.0; Mid [Cl−]i at baseline = 5.0 ± 1.4 and 
E-act = 23.3 ± 2.0}. There were no E-act induced APs in 
DRG neurons with Low [Cl−]i (n = 3). AP firing at base-
line and during E-act (10  µM) perfusion are illustrated 
in Vm-time plots for represented DRG neurons with 
intracellular solutions of: high [Cl−]i, mid [Cl−]i and low 
[Cl−]i (Fig. 2c). In these graphs, Vm recordings are shown 
above ˗30  ±  10  mV (voltages below ˗40  mV occurred 
but are not shown). E-act-induced AP firings of DRG 
neurons were independent of other known ANO1 acti-
vators: [Ca2+]i and temperatures above 27 °C (Recording 
electrode solutions were devoid of Ca2+ and recordings 
occurred at room temperature, ~22 °C).
ANO1 outward rectifying currents in Fig. 1b, c, would 
imply that ANO1 would carry large influxes of Cl− at the 
positive potentials of APs. This could result in ANO1 
channel activation enhancing the repolarization phase of 
APs. However, when we compared individual APs spon-
taneously occurring at baseline to APs induced by E-act 
application in the same DRG neurons, the APs were simi-
lar in their depolarization and repolarization phases. This 
is illustrated in the insert of Fig.  2d with the spontane-
ous baseline AP superimposed by the E-act induced AP. 
We did observe a delay of the initiation of APs induced 
by E-act, as the two APs indicate in the representative 
DRG neuron of Fig. 2d. The delay between the APs was 
statistically significant for DRG neurons with physio-
logical [Cl−]i. However, Vm at the repolarization/resting 
potential phase of the current pulse also often decreased 
by 10-20 mV over the time course of the experiment and 
could explain these results. {Average time of AP peak 
voltage occurred at: baseline = 437.6 ± 1.4 ms, n = 15; 
E-act = 443.9 ± 0.7 ms, n = 40; p < 0.001}.
E‑act induces nocifensive behaviors
APs in nociceptor neurons result in the synaptic release 
of glutamate and neuropeptides that activate spinal/
brainstem neurons to transmit signals for pain percep-
tion by the brain. Our findings that E-act triggers APs 
in  vitro could, thus, translate to E-act inducing periph-
eral pain-associated nocifensive behavioral responses in a 
mouse model in vivo. Therefore, nocifensive responses to 
paw injections (licks, flicks and lifts) were video recorded 
over 5 min. A single behavior, such as paw lift, could be 
maintained for a long time (over 1 min). Hence, not only 
the number of behavioral responses, but also the lengths 
of time for the responses were quantified. Immediately 
following subplantar 25  μl injections of E-act (5  mM) 
into the hind paw, mice displayed vigorous nocifensive 
responses that were significantly more in total number 
and time spent performing than the nonexistent effects 
Page 6 of 15Deba and Bessac  Mol Pain  (2015) 11:55 
of vehicle injections in the contralateral paw (Fig.  3a, 
b). {Average total behaviors induced by: E-act (num-
ber = 39.7 ± 6.5 and time spent = 117.2 ± 20.6); vehicle 
(number = 0.7 ± 0.3 and time spent = 0.6 ± 1.5); n = 6}. 
Nocifensive responses to 5  mM E-act were significantly 
reduced when co-injected with 1.3  mM ANO1-inh 
(Fig.  3c, d). {Average total behaviors induced by: E-act 
(number  =  52.7  ±  7.7 and time spent  =  231.7  ±  24); 
ANO1-inh with E-act (number  =  19.8  ±  2.5 and time 
spent = 66 ± 8.7; n = 6}. The data suggest ANO1 activa-
tion by E-act induces peripheral pain that can be attenu-
ated by ANO1-inh.
T16A[inh]‑A01 attenuates capsaicin evoked firing of action 
potentials by DRG neurons
ANO1 are Ca2+-gated Cl− channels found in a variety 
of tissues, and many of ANO1 physiological functions 
involve gating by intracellular Ca2+ [14]. In sensory 
neurons, ANO1 gating by [Ca2+]i (via IP3 receptor cou-
pling) mediates bradykinin (BK) B2 receptor triggering of 
APs (K+ channel inhibition, and TRP channels are also 
involved) [6]. Lowering [Cl−]i to shift ECl- to be more 
negative, renders ANO1 to be inhibitory and thereby 
suppresses bradykinin triggering of APs [6]. Bradykinin-
evoked APs of sensory neurons, mediated by ANO1, 
are also suppressed by ANO1-inh or non-specific Cl− 
channel blockers. (This was verified in our lab; data not 
shown).
Activation of other sensory neurons receptors, such 
as TRPV1, increase [Ca2+]i that could gate ANO1. Heat, 
acidity, and capsaicin activate sensory neuronal TRPV1 
channels to carry an influx of cations including Ca2+ that 
can trigger APs. ANO1 and TRPV1 directly interact and 
are co-expressed in sensory neurons [24, 32]. We propose 
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that at high or physiological [Cl−]i, TRPV1-carried 
[Ca2+]i activates ANO1. Subsequently, ANO1-carried 
Cl− efflux positively feeds back to increase depolarization 
and thus increase the triggering of APs. ANO1-inhibitors 
would block ANO1 channels’ contribution to depolari-
zation thereby diminishing TRPV1-triggered APs. Con-
versely, at low [Cl−]i, activation of ANO1 would inhibit 
TRPV1; moreover, ANO1-inhibitors would have little 
influence.
ANO1 modulation of capsaicin-induced action poten-
tials in DRG neurons was measured by Ca2+ imperme-
able perforated-patch (Amphotericin-B) current-clamp 
technique to not disrupt TRPV1 carried-Ca2+ activa-
tion of ANO1. Currents were injected as described in 
the methods and shown in Fig. 2a. In our hands, it was 
not possible to determine ANO1 and TRPV1 co-activa-
tion using voltage-clamp because TRPV1 currents mask 
ANO1 current–voltage curves. Therefore, we examined 
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if inhibition of ANO1 channels would remove the facili-
tation, and thus, lower TRPV1-mediated AP firing in 
DRG neurons. Perfusion of a saturating dose of capsaicin 
(15  µM) evoked robust DRG neuron AP firing that was 
significantly reduced by ANO1-inh (20 µM) mixed with 
capsaicin. This observation occurred when DRG neuron 
[Cl−]i was altered to 160  mM (High [Cl−]i) or 40  mM 
(Mid [Cl−]i) by the recording-pipette milieu (Fig.  4a). 
{Average APs for: High [Cl−]i at baseline = 5 ± 0.4, capsai-
cin = 22.8 ± 1.1 and ANO1-inh & capsaicin = 11.6 ± 3.0, 
n  =  5; Mid [Cl−]i at baseline  =  4.3  ±  0.3, capsai-
cin = 20.6 ± 0.7 and ANO1-inh & capsaicin = 8.0 ± 1.2, 
n = 3}. APs over the time course of the experiment are 
shown in representative DRG neurons with High [Cl−]i 
and Mid [Cl−]i (Fig. 4b). Although, the results were simi-
lar to a simultaneous publication; a perplexing difference 
was that they recorded a series of APs induced by cap-
saicin with current injection continuously held near 0-pA 
for more than 10-s [32]. In our study, only one AP was 
recorded for a 0-pA current injection segment that lasted 
0.12 or 0.4 s.
We then explored ANO1 modulation of capsaicin-
induced APs in DRG neurons with Low [Cl−]i (10 mM). 
At Low [Cl−]i, capsaicin (15  µM) still induced pro-
nounced DRG neuron AP firing, which was significantly 
suppressed by co-application of ANO1-activator E-act 
(10  µM). Subsequently, co-application of ANO1-inh 
(20 µM) with capsaicin rescued AP firing back to levels 
of capsaicin alone (Fig. 4c). In Fig. 4d, APs over the time 
course of the experiment are shown in a representative 
DRG neuron with Low [Cl−]i. AP firing induced by cap-
saicin and induced by capsaicin with ANO1-inh were 
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not significantly different from each other. They were sig-
nificantly greater than the number of APs that occurred 
at baseline and with co-application of capsaicin with 
E-act. {Average APs for: baseline  =  3.3  ±  1.3; capsai-
cin = 24.8 ± 0.3; E-act & capsaicin = 9.5 ± 1.0; ANO1-
inh & capsaicin = 21.0 ± 1.3; n = 4}. AP firing frequency 
induced by capsaicin was not significantly reduced in 
experiments with a sequential second perfusion of cap-
saicin (data not shown).
Capsaicin‑induced nocifensive behaviors are attenuated 
by T16A[inh]‑A01
ANO1 channels are involved in nocifensive responses 
to a variety of noxious stimuli. Nocifensive behavioral 
responses to noxious heat, bradykinin and formalin have 
been significantly reduced in mice that lack functional 
ANO1 in their somatosensory neurons [6–9]. Capsaicin 
activation of somatosensory neuronal TRPV1 induces 
painful sensations [27]. In the prior section, we demon-
strated that pharmacological inhibition of primary cul-
tured DRG neuronal ANO1 diminished the frequencies 
of APs induced by capsaicin, in  vitro. In this section, 
we examined if pharmacological inhibition of ANO1 
could attenuate capsaicin-induced nocifensive behav-
iors in vivo. As expected, subplantar 25 μl injections of 
capsaicin (50  µM) into mice hind paws induced vigor-
ous nocifensive behaviors of licking, flicking and lifting. 
The nocifensive behavioral responses to capsaicin were 
significantly less in number and time spent performing 
when the injected solution of 50 µM capsaicin was mixed 
with 1.3 mM ANO1-inh (following a pretreatment inject 
of the paws with 1.3 mM ANO1-inh 2 h earlier) (Fig. 5a, 
b). Time spent in nocifensive behavioral responses were 
further quantified by minutes following injection of 
capsaicin or ANO1-inh co-application/pre-treatment 
(Fig.  5c). {Average total behaviors induced by: capsai-
cin (number = 50.3 ± 2.9 and time spent = 164 ± 12.5); 
capsaicin with ANO1-inh (number  =  30.6  ±  1.3 and 
time spent =  60.5 ±  4.3); n =  8}. Vehicle (control) pre-
treatment of the paws induced a significant increase 
(p  <  0.05) in nocifensive responses to a following injec-
tion of 50 µM capsaicin {Average total of behaviors (num-
ber = 60.3 ± 2.8; time spent = 236 ± 17.2); n = 6} than 
naïve paws injected with capsaicin. The data suggests 
that pain evoked by TRPV1 activation can be reduced 
by inhibiting ANO1. Thus, the data indicate ANO1 are 
involved in facilitating TRPV1 actions to evoke pain and 
inhibition of ANO1 could evoke analgesia.
Discussion
Management of chronic peripheral pain is a major medi-
cal issue. In the last decades, great strides have been 
made in understanding the molecular mechanisms 
involved in pain generation and perception, and new 
treatments have resulted. Key cellular components of 
peripheral pain generation are nociceptors (somatosen-
sory neurons). Noxicants and mediators of tissue inflam-
mation and injury evoke action potentials (APs) that send 
signals to the spine and brainstem for eventual pain per-
ception by the brain [4]. Nociceptors are ideal targets for 
treatments of pain. However, the molecular biology of 
nociceptors, and thus potential target sites, are not well 
defined. Recently, sensory neuronal Anoctamin 1 Ca2+–
gated Cl− channels (ANO1) have been demonstrated to 
transduce signals for the generation of peripheral pain in 
response to environmental and inflammatory signals [6–
8, 32]. In sensory neurons, ANO1 and other Cl− channels 
are excitatory due to the relatively high levels of intra-
cellular Cl− ([Cl−]i) [18]. ANO1 channels are activated 
by intracellular Ca2+ ([Ca2+]i), heat and pharmacologi-
cal reagents, such as an N-aroylaminothiazole, E-act [17, 
18]. We explored direct activation of ANO1 by E-act to 
strengthen the evidence that activation of sensory neu-
ronal ANO1 Cl− channels are an important molecular 
mechanism for the generation of peripheral pain. We 
found E-act triggers APs in sensory neurons. Interest-
ingly, E-act effects were dependent upon [Cl−]i but inde-
pendent of heat or [Ca2+]i. Furthermore, E-act induces 
vigorous pain-associated nocifensive behaviors by mice 
in vivo.
Sensory neuronal [Cl−]i is approximately 40  mM; this 
anion concentration determines that ANO1 and other 
Cl− channels have a reversal potential (Cl− electrochemi-
cal equilibrium (ECl-)) near −30 mV [18]. Therefore, sen-
sory neuronal ANO1 carries depolarizing Cl− effluxes 
that could activate voltage-gated Na+ channels responsi-
ble for AP propagation. However, we repeatedly observed 
that sensory neuronal ANO1, activated by E-act, have 
outwardly rectifying current–voltage curves, similar 
to current–voltage curves recorded of native ANO1 in 
other tissues [6, 33]. This would imply that ANO1 car-
ries relatively small currents associated with Cl− effluxes. 
Possibly, currents of other channels, voltage regulation of 
ANO1, [Ca2+]i modulation of ANO1 currents or other 
factors, are masking ANO1 carried inward currents 
(Cl− effluxes) in the sensory neuronal current–voltage 
curves. In our studies, E-act-induced sensory neuronal 
ANO1 carried Cl− effluxes (inward currents) that were 
large enough to depolarize the membrane to activate 
voltage-gated Na+ channels. E-act-induced APs were 
dependent upon [Cl−]i being 40  mM or higher, which 
indicates Cl− channel involvement. Studies of membrane 
receptor-activated sensory neuronal ANO1 (via [Ca2+]i) 
have reported larger inward currents carried by ANO1 
(>400 pA), when the membrane was held at −60 mV [7, 
32]. Inward current sizes of ANO1 are known to vary 
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depending upon [Ca2+]i levels in recombinant models 
[38]. ANO1 outward rectifying currents would also imply 
that ANO1 carry large influxes of Cl− once APs are acti-
vated. Thus, ANO1 could enhance the repolarization 
phase of APs at depolarizing potentials. When we com-
pared individual APs spontaneously occurring at baseline 
and APs induced by E-act application in the same DRG 
neurons, the APs were similar. However, a complete bio-
physical investigation of ANO1 channel carried ions in 
the initiation and repolarization of APs is needed, espe-
cially at different [Cl−]i.
Sensory neuronal ANO1 channels are involved in the 
physiology of acute peripheral pain responses to heat and 
inflammatory signaling. ANO1 channels are one of sev-
eral thermosensitive ion channels in sensory neurons that 
detect harmfully high temperatures and subsequently 
evoke APs to signal for painful ‘hot’-associated nocif-
ensive responses [8]. Sensory neuronal B2 and PAR-2 
GPCRs detection of bradykinin and proteases released 
by injured or inflamed tissues results in an increase of 
[Ca2+]i (via IP3 receptors) that activates ANO1. Thereby, 
ANO1 carry a depolarizing Cl− flux that mediates these 
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Fig. 5 ANO1-inhibitor attenuates mouse nocifensive behavior responses to capsaicin. The average number (a) and time spent in (b) nocifensive 
behavior responses (licks, flicks, lifts and total responses) by mice hind paws (n = 8) to subplantar injections of 50 µM capsaicin (Cap black bar) were 
significantly more than subplantar injections of an Ano1-inhibitor 1.3 mM T16A[inh]-A01 mixed with 50 µM capsaicin (Cap + Ano1-inh, white bar) in 
contralateral paws, (pre-treated injection was given 2 h earlier with 1.3 mM Ano1-inh). c Average total time spent performing nocifensive behaviors 
at each minute increment (1-hrough 5th minute following injection of capsaicin (Cap black bar) or Ano1-inh mixed with capsaicin (Cap + Ano1-inh, 
white bar), as described for (b). All nocifensive behaviors were quantified from videos of the 5 min. immediately following subplantar injections. 
Injection regimens occurred on different days and opposite paws of the same mice. Error bars are SE. (***p > 0.001, **p > 0.01, *p > 0.05)
Page 11 of 15Deba and Bessac  Mol Pain  (2015) 11:55 
sensory neuronal GPCRs firing of APs and subsequent 
nocifensive responses at the site of injury [6, 7]. Conceiv-
ably, sensory neuronal ANO1 gating by raised [Ca2+]i, 
the unknown mechanisms of the intrinsic thermosensor 
or the unknown mechanisms of E-act, could be involved 
in various physiological and pathological conditions of 
heightened and chronic peripheral pain. Targeting sen-
sory neuronal ANO1 with pharmacological antagonists 
could diminish peripheral pain of these conditions. 
Nocifensive behavioral responses to noxious heat, brady-
kinin and formalin have been shown to be significantly 
reduced in mice with functional ablation of ANO1 in 
their sensory neurons [8, 9]. We find that pharmacologi-
cal inhibition of ANO1 suppresses E-act induced pain-
associated nocifensive behaviors. Moreover, we find that 
an ANO1 inhibitor attenuates the triggering of APs and 
nocifensive behavioral responses induced by the sensory 
neuronal, noxious heat sensor, TRPV1.
TRPV1, TRPV4, TRPA1 and several other TRP chan-
nels are expressed in sensory neurons and are involved 
in somatosensory detection and nocifensive responses 
to environmental temperatures and reactive chemi-
cals [22, 40, 42]. Recently, TRPV1 was shown to inter-
act with ANO1 in cell membranes and carries Ca2+ into 
cells that thereby activates ANO1 in sensory neurons 
and co-transfected HEK-293 cells [32]. We and others 
postulate that TRPV1 carried [Ca2+]i-activates ANO1 
[32]. The combined cation influxes carried by TRPV1 
and anion effluxes carried by ANO1 would increase the 
size and speed of membrane depolarization and thus 
enhance the triggering of action potentials and subse-
quent pain perception [43]. Simultaneous with another 
laboratory’s findings, this hypothesis was tested and sup-
ported by our demonstration that blocking ANO1 chan-
nels will attenuate TRPV1 activator, capsaicin, induced 
firing of sensory neuronal APs and mouse nocifensive 
behavioral responses associated with pain [25–28, 32]. 
Similar to TRPV1, ANO1 could facilitate other sensory 
neuron TRP channels. TRPV4 carried [Ca2+]i activation 
of ANO1 occurs in epithelia cells of the choroid plexus 
and in HEK-293 cells co-transfected with TRPV4 and 
ANO1, but has not yet been examined in neurons [33]. 
Sensory neuronal TRPA1 responds to reactive chemicals, 
such as formalin [4, 44]. Interestingly, formalin-induced 
nociception also involves ANO1 and TRPV4 [45, 46]. 
Perhaps nociceptor neuron depolarization by formalin 
activation of TRPA1 or TRPV4 is amplified by ANO1.
The mechanisms by which ANO1 interact with changes 
of [Ca2+]i generated by membrane receptors in sensory 
neurons are controversial [7, 31]. Evidence suggests that 
sensory neuronal ANO1 are directly coupled with IP3 
receptor complexes to provide Ca2+ in close proximity to 
gate ANO1 and to protect against cytosolic [Ca2+]i from 
enhancing ANO1 sensitivity to heat or activating ANO1 
to consequently produce pain [7]. This could explain why 
DRG neuronal ANO1 do not appear to be activated by 
increased [Ca2+]i from voltage-gated Ca2+ channels 
[7]. TRPV1 carried [Ca2+]i activates phospholipase Cδ 
(PLCδ). PLCδ cleaves IP3 to open IP3 receptor channels 
and thus could be the intermediator in TRPV1 activa-
tion of ANO1 [47, 48]. An alternative explanation is that 
TRPV1 direct coupling with ANO1 allows for TRPV1 
channels to deliver large [Ca2+]i in close proximity to 
activate ANO1 independent of IP3 receptors [32].
In addition to proteases and bradykinin, various other 
factors serve as signals of tissue damage and inflamma-
tion. The ‘inflammatory soup’ of factors (neurotropins, 
prostaglandins, ATP, serotonin, histamine, thymic stro-
mal lymphopoietin, other cytokines…) activate metabo-
tropic receptors and ion channels on adjacent sensory 
neuronal processes that increase [Ca2+]i and trigger APs, 
resulting in pain, pruritus and nocifensive responses to 
the injured, inflamed area [49–51]. In other cell types, 
inflammatory factors activate ANO1 channels by Ca2+ 
release via IP3 receptor in a manner similar to PAR2 
and B2 GPCRs [43, 52]. ANO1 could be involved in the 
various inflammatory factors activation of nociceptor 
neurons and transduction of pain. Thus, pharmacologi-
cal antagonists of ANO1 could attenuate a variety of the 
peripheral mechanisms of acute inflammatory pain; in 
addition to attenuating the acute pain induced by TRPV1 
or the detection of environmental hazards by other TRP 
channels.
Recent evidence suggests that sensory neuronal ANO1 
Cl− channels are involved in hyperalgesia and allodynia 
from tissue inflammation and peripheral neuropathy. 
Sensory neurons innervating inflamed tissues become 
hyperexcitable as a result of continuous exposure to 
‘inflammatory soup’ signaling factors. These hyperexcit-
able sensory neurons contribute to the hyperalgesia and 
allodynia from inflammation. Genetic ablation of func-
tional ANO1 in mouse sensory neurons results in dimin-
ished hyperexcitablity of sensory neurons incubated with 
‘inflammatory soup’ factors. Furthermore, hyperalgesia 
and allodynia-like responses to heat and mechanical pres-
sure in inflamed mouse paws and in paws with a dam-
aged sciatic nerve are diminished for mice with ablation 
of functional ANO1 in sensory neurons [9]. Continuous 
exposure to ‘inflammatory soup’ signaling factors alters 
sensory neuronal intracellular Cl− homeostasis resulting 
in continuously high [Cl−]i, which has a role in hyperex-
citability [53, 54]. We hypothesize that ANO1 Cl− chan-
nels’ contribution to inflammatory hyperalgesia involves 
the high [Cl−]i. The positive shift of ECl- due to the 
heightened [Cl−]i levels would shift ANO1 channels’ Cl− 
effluxes to readily occur at more depolarized potentials 
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and with larger current sizes at negative potentials [40]. 
Thus, APs and pain perception triggered by noxious stim-
uli activation of sensory neuronal TRPV1 channels, brad-
ykinin receptors and other receptors would be amplified 
in inflammatory conditions by co-activated ANO1 chan-
nels carrying larger depolarizing Cl− effluxes. However, 
in our studies, high [Cl−]i (160  mM) did not alter sen-
sory neuron responses to capsaicin or E-act compared to 
physiological [Cl−]i (40 mM). Possibly at lower doses of 
capsaicin or E-act, differences between high and physi-
ological [Cl−]i modulation of sensory AP firing might 
be observed. In the opposite scenario, we observed that 
ANO1 channels inhibited AP firing by E-act or capsaicin 
of sensory neurons with low [Cl−]i (10  mM). This phe-
nomenon is similar to fetal brain neuronal Cl− channels, 
which trigger APs due to high [Cl−]i, in contrast adult 
brain neuronal Cl− channels inhibit AP generation due to 
low [Cl−]i [54]. These findings support evidence that low-
ering sensory neuron [Cl−]i favors analgesia and suggests 
a role of ANO1 in the increased [Cl−]i levels that evoke 
inflammatory hyperalgesia [53, 54].
Conclusion
In summary, our results provide strong evidence of a 
role for somatosensory neuronal ANO1 Ca2+-gated Cl− 
channels in the molecular mechanisms of nociception 
transduction. We report that: (1) direct pharmacological 
activation of ANO1 channels induces [Cl−]i-dependent 
AP firing in DRG neurons and (2) this is translated 
into ANO1 activation that evokes nocifensive behav-
iors associated with pain. Furthermore, we provide 
indirect evidence that ANO1 channels are involved in 
TRPV1-induced firing of APs and nocifensive behavioral 
responses. We demonstrated that: (1) pharmacological 
inhibition of ANO1 attenuates AP firing by DRG neu-
rons from TRPV1 activation by capsaicin (dependent 
upon [Cl−]i) and (2) co-treatment with an ANO1 inhibi-
tor alleviated capsaicin-induced nocifensive behavioral 
responses by mice.
Billions of dollars are spent on prescribed and over-
the-counter medications to alleviate peripheral pain 
[2]. We show that pharmacological inhibition of ANO1 
attenuates capsaicin-induced nocifensive responses in a 
mouse model of peripheral pain. Others have shown that 
pharmacological inhibition or genetic ablation of sensory 
neuronal ANO1 attenuates mouse nocifensive responses 
to bradykinin, formalin and heat, as well as diminishing 
inflammatory hyperalgesia and neuropathic hypersensi-
tivity [6, 8, 9]. Most likely ANO1 are involved in the noci-
ception to a variety of noxious stimuli and pathological 
conditions. Therefore, inhibiting ANO1 channels have 
great potential as a new target for analgesics.
Methods
Animals
Female, 12–20  week old, Balb/c mice were housed at 
AALAC-accredited facility in standard environmental 
conditions (food/water ad  libitum, 12  h light/dark light 
cycle, RT 24  °C). Animals were habituated before test-
ing of in  vivo experiments. All animal procedures were 
approved by the IACUC committee of Texas A&M 
Health Science Center-Institute of Biotechnology.
Dorsal root ganglia harvest
Adult mouse dorsal root ganglia (DRG) somatosensory 
neurons were dissected immediately following death 
by CO2 euthanasia and dissociated by 1 h incubation in 
0.26 WU/ml Liberase TM (Roche), followed by washes 
with Hank’s solution, trituration, and straining of debris 
(40 μM Cell Strainer; BD Falcon). Neurons were cultured 
in neurobasal-A medium (Invitrogen) with B-27 supple-
ment, 0.5  mM glutamine, and 50  ng/ml nerve growth 
factor (Calbiochem) on 35 mm cell culture dishes coated 
with poly-d-lysine (Sigma-Aldrich) and laminin (Invitro-
gen). Cells were placed in an incubator in 95  % air/5  % 
CO2 atmosphere at 37 °C [56].
Cell‑line Culture and Transfection
HEK-293t cells were grown in Dulbecco’s modified Eagle 
medium (Gibco) with 10  % fetal bovine serum and 1  % 
penicillin/streptomycin at 37  °C in 5  % CO2. Cells were 
transiently transfected using Lipofectamine (Invitrogen) 
with 500  ng cDNA encoding mouse ANO1/TMEM16A 
in a mammalian expression vector fused with pEGFP flu-
orescent reporter [10]. Mouse ANO1/TMEM16A cDNA 
and plasmid was a generous gift from L. Jan laboratory 
(UCSF, San Francisco, CA). Transfected cells were incu-
bated at 30–50  % confluency on poly-d-lysine coated 
glass coverslips overnight and identified for electro-
physiology by GFP fluorescence using FITC filter (31001, 
Chroma).
Electrophysiology
The day following (16–26  h) DRG dissection or trans-
fection of cells, patch clamp electrophysiological 
experiments were performed in the perforated-patch 
(amphotericin-B, 250 μg/ml; MP Biomedicals) or whole-
cell configurations with borosilicate micropipettes 
(GC150T, Harvard Apparatus) of resistances 2–5  MΩ 
pulled by PMP102 apparatus (Micro Data Instruments). 
EPC-10 Plus amplifier coupled with an analogue–digital 
converter (HEKA, Germany) recorded and manipulated 
voltages that were interpreted by PatchMaster software 
(V2X60). Bath solution contained (in mM): 140 NaCl, 5 
KCl, 2 MgCl2, 2 CaCl2, 10 Hepes and 5 glucose (pH 7.3). 
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A perfusion system exchanged prior bath solutions to 
bath solutions containing: 10  µM E-act (3,4,5-trimeth-
oxy-N-(2-methoxyethyl)-N-(4-phenylthiazol-2-yl)benza-
mide; EMD Chemicals [18]) or 15  µM capsaicin (Enzo) 
with or without 20  µM ANO1-inh (T16A[inh]-A01; 
2-[(5-ethyl-1,6-dihydro-4-methyl-6-oxo-2-pyrimidinyl)
thio]-N-[4-(4-methoxyphenyl)-2-thiazolyl] acetamide; 
EMD Chemicals [34]). In certain experiments 10  µM 
ruthenium red (Enzo) was also in the perfused bath solu-
tion. Liquid junction potentials were calculated by Igor 
Pro software Patcher’s Power Tools (Wavemetrics) and 
adjusted for in PatchMaster.
Voltage-clamp high resolution currents were filtered 
at 2.3 kHz and digitalized at 100 µs intervals with hold-
ing potential of −70  mV or 0  mV, at every second volt-
age-ramps of −100 to +100  mV over 200  ms occurred 
as described previously [55]. Recording pipette solution 
contained (in mM): 150 CsCl, 2 MgCl2, 2.3 Na3ATP, 1.1 
EGTA, 10 Hepes; pH 7.2. In certain experiments, free 
[Ca2+] was not 0, but was adjusted to 1  µM or 10  µM 
with addition of 1 mM or 1.12 mM CaCl2 as determined 
by Webmaxc, http://www.stanford.edu/~cpatton/web-
maxcS.htm.
Current-clamp voltages were recorded using either 
amphotericin B-perforated patch (250  µg/ml) or whole 
cell configuration [6]. Initially, voltage-clamp was estab-
lished as described above. If voltage-gated channels were 
noticeable, then current-clamp was begun. Using voltage 
ramps of −100 to +100 mV, the following reversal poten-
tials were determined for the experimental groups: extra-
cellular capsaicin (perforated-patch) with High [Cl−]i at 
−42 ± 3 mV, Mid [Cl−]i at −51 ± 9 mV and Low [Cl−]i 
at −41  ±  6  mV; extracellular E-act (whole-cell) with 
High [Cl−]i at -60 ± 2 mV, Mid [Cl−]i at −28 ± 5 mV and 
Low [Cl−]i at -54 ±  2  mV. Before beginning membrane 
voltage potential (Vm) recordings, empirical measure-
ments identified current injection sizes required to bring 
Vm to −70 ±  10 mV (to “reset” voltage-gated channels) 
and to −30 ± 10 mV (just below the voltage required to 
activate voltage-gated channels) for that specific DRG 
neuron. There appeared to be a technical issue in our 
current clamp that up to −100 pA current injection was 
necessary to lower Vm to −70  mV and approximately 
0 pA injection for Vm of −30  mV. This could be due to 
faulty-sealed “leaky” patches in those patches with rever-
sal potential near -30 mV. A sequence of square pulses of 
current injections with the following current injection 
protocol were employed to record Vm: 1) [−40 to −100] 
pA for 400 ms (to hold Vm near −70 mV); 2) 0 ± 10 pA 
for 400 ms (to bring Vm near −30 mV); 3) [−40 to −100] 
pA for 20  ms; 4) 0 ±  10 pA for 120  ms; and 5) (−40 to 
−100 pA) for 100 ms [40] (see Fig. 2a). Action potentials 
(APs) only occurred during the 0-pA current injection 
segments of the protocol. Perplexing to the authors was 
that, at most, only one AP was observed for a 0-pA cur-
rent injection segment and not a series/“train” of APs. 
The sequence of current injections was identical in per-
forated patch current-clamp voltage recordings. Only Vm 
“spikes” above 10  mV were considered as APs. Record-
ing pipette solution for high [Cl−]i condition contained 
(in mM): 150  KCl, 5 MgCl2, 10 HEPES, pH 7.4. Low 
[Cl−]i condition solutions were identical, except KCl was 
replaced by equimolar K-gluconate. Mid [Cl−]i condition 
solutions contained (in mM): 30 KCl, 110 K-gluconate, 5 
MgCl2, 10 HEPES.
Nociceptive behavior
Mouse hind paws received intraplantar injections of 
25  μl of pharmacological reagent or vehicle using a 
50  μl Hamilton syringe and 30G needle. Both experi-
mental and control conditions were investigated within 
the same mice. To control for injection sequence, half 
of the mice in the experimental group received the hind 
paw injection(s) for one condition, while the other half 
received hind paw injection(s) of a different condition. 
The next day, mice received in the opposite hind paw 
the injection(s) of the condition that they had not yet 
received. The vehicle for all solutions was (v/v) 95 % pro-
pylene glycol and 5  % DMSO. In one experiment, mice 
were injected with vehicle in the left hind paw and ANO1 
activator (5 mM E-act) in the right hind paw, in the man-
ner just described. In a separate experiment (with sepa-
rate mice), mice were injected with 5  mM E-act in the 
right hind paw and ANO1 inhibitor (1.3 mM T16A[inh]-
A01; ANO1-inh) with 5 mM E-act in the left hind paw. 
In capsaicin experiments (again with separate mice), 
mice received an initial injection in the right hind paw 
of ANO1 inhibitor (1.3  mM T16A[inh]-A01; ANO1-
inh) followed 2 h later with an injection of a mixture of 
1.3  mM ANO1-inh with 50  µM capsaicin in the same 
paw or they received an injection of just 50 µM capsaicin 
in the left paw. As a further experimental control (with 
separate mice), 50  µM capsaicin paw injections were 
given in paws injected with vehicle 2 h earlier. Mice were 
placed in a Plexiglas enclosure and videotaped for 5 min 
immediately following final hind paw injections. Nocifen-
sive behavior responses (paw flicking, lifting, and licking) 
were quantified by slowing the video frame speed with 
Windows Media player software [57].
Statistics
For all statistical tests, a p value less than 0.05 was con-
sidered significant. Statistical analysis and graphic dis-
play of electrophysiological records were made with Igor 
Pro (Wavemetrics). Statistical errors were the standard 
error (SE). Average total action potential propagations 
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were assessed by a one-way repeated measures ANOVA, 
followed by post hoc analysis with Bonferroni multi-
comparison test (SPSS). Dependent (repeated-measure) 
Student’s t were performed on average time of AP volt-
age peak and the number and time (either over a min or 
5 min) spent flicking, lifting, licking and total nociception 
responses to injections of: (1) vehicle compared to ANO1 
activator E-act, (2) E-act compared to ANO1 inhibitor 
T16A[inh]-A01 with E-act, and (3) capsaicin compared 
to capsaicin with T16A[inh]-A01.
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